Termination of Registration of a Class of Security Under Section 13 and 15(d) (15-15d)
13 Julio 2020 - 12:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF
REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF
1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND
15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number
333-156480
PEAK PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 85260
Telephone: (480) 659-6404
(Address, including zip code, and telephone number, including area
code, of registrant’s principal executive
offices)
Common Stock, par value $0.0001 per share
(Title of each class of securities covered by this
Form)
None
(Titles of all other classes of securities for which a duty to file
reports under section 13(a) or 15(d) remains)
Please
place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file
reports:
|
Rule
12g-4(a)(1)
|
|
☒
|
|
Rule
12g-4(a)(2)
|
|
☒
|
|
Rule
12h-3(b)(1)(i)
|
|
☐
|
|
Rule
12h-3(b)(1)(ii)
|
|
☐
|
|
Rule
15d-6
|
|
☐
|
Approximate
number of holders of record as of the certification or notice date:
19
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated:
July 13, 2020
|
|
|
|
|
PEAK PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
|
/s/ Neil Reithinger
|
|
Name:
|
|
Neil
Reithinger
|
|
Title:
|
|
Chief
Executive Officer
|
Peak Pharmaceuticals (PK) (USOTC:PKPH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Peak Pharmaceuticals (PK) (USOTC:PKPH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
